Eplerenone 25 mg Oral Tablet
RxNorm 351256
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 351256 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: eplerenone 25 mg Oral Tablet.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCDPrescribable
Semantic Clinical Drug (SCD):
Eplerenone 25 mg Oral Tablet
(Atom ID: 1546962)
PSNPrescribable
Prescribable Name (PSN):
Eplerenone 25 mg Oral Tablet
(Atom ID: 6367782)
PTPrescribable
Designated preferred name (PT):
Eplerenone 25 mg oral tablet
(Atom ID: 9250330)
FNPrescribable
Full form of descriptor (FN):
Product containing precisely eplerenone 25 mg/1 each conventional release oral tablet (clinical drug)
(Atom ID: 10312029)
Patient Education
Eplerenone
Eplerenone is used alone or in combination with other medications to treat high blood pressure. Eplerenone is in a class of medications called mineralocorticoid receptor antagonists. It works by blocking the action of aldosterone, a natural substance in the body that raises blood pressure. High blood pressure is a common condition and when not treated, can cause damage to the brain, heart, blood vessels, kidneys and other parts of the body. Damage to these organs may cause heart disease, a heart attack, heart failure, stroke, kidney failure, loss of vision, and other problems. In addition to taking medication, making lifestyle changes will also help to control your blood pressure. These changes include eating a diet that is low in fat and salt, maintaining a healthy weight, exercising at least 30 minutes most days, not smoking, and using alcohol in moderation.
[Learn More]
* Please review the disclaimer below.